- 中国科学论文统计源期刊
- 中国科技核心期刊
- 美国化学文摘(CA)来源期刊
- 日本科学技术振兴机构数据库(JST)
临床输血与检验 ›› 2021, Vol. 23 ›› Issue (5): 578-584.DOI: 10.3969/j.issn.1671-2587.2021.05.008
陈清艳, 王秋实
收稿日期:2021-07-21
出版日期:2021-10-20
发布日期:2021-10-20
通讯作者:
王秋实,女,教授,主任医师,博士,主要从事血液管理及胎母免疫方面研究,（E-mail）wangqs18@vip.126.com。
作者简介:陈清艳（1996-）,女,湖北建始人,硕士研究生在读,主要从事妇产科学基础方面研究,（E-mail）chenqingyan0423@163.com。
基金资助:
Received:2021-07-21
Online:2021-10-20
Published:2021-10-20
摘要： 胎儿和新生儿溶血病 （hemolytic disease of fetus and newborn,HDFN） 是母体针对非自身红细胞抗原发生的红细胞同种异体免疫,引起溶血和/或抑制红细胞生成。红细胞同种抗体作为HDFN发病的直接原因,其产生机制和胎盘转运效率与疾病预防和治疗密切相关。本文就近年来HDFN的发病机制、产前风险评估做一综述,为进一步了解HDFN的发病过程以及寻找新的预防措施提供一定的参考。
中图分类号:
陈清艳, 王秋实. 新生儿溶血病发病机制及产前诊断研究进展*[J]. 临床输血与检验, 2021, 23(5): 578-584.
| [1] HAIDER M,MEMON S,TARIQ F,et al.Rhesus isoimmunization: late-onset hemolytic disease of the newborn without jaundice[J].Cureus,2020,12(1): e6559. [2] American Academy of Pediatrics Subcommittee on Hyperbilirubinemia.Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation[J].Pediatrics,2004,114(1):297-316. [3] 张钰,张璐,许纪玲,等.1300例新生儿溶血病血型血清学检测结果分析[J].中国输血杂志,2020,33(9):922-924. [4] 杜肖刚,王丽荣,段燕军.未孕女性IgG类抗A(B)抗体效价测定分析[J].长治医学院学报,2016,30(2):137-139. [5] 周明,王慧茹,陈洋,等.孕产妇Rh血型系统抗体检测和临床意义分析[J].安徽医药,2020,24(2):252-256. [6] YAMAMOTO F,CID E,YAMAMOTO M,et al.An integrative evolution theory of histo-blood group ABO and related genes[J].Sci Rep,2014,4:6601. [7] CAI X, JIN S, LIU X,et al.Molecular genetic analysis of ABO blood group variations reveals 29 novel ABO subgroup alleles[J]. Transfusion, 2013. 53(11 Suppl 2):2910-2916. [8] YING Y,HONG X,XU X,et al.Serological characteristic and molecular basis of A2 subgroup in the Chinese population[J].Transfus Apher Sci,2013,48(1):67-74. [9] WESTHOFF C M.The structure and function of the Rh antigen complex[J].Semin Hematol,2007,44(1):42-50. [10] FLEGEL W A,DENOMME G A,QUEENAN J T,et al.It's time to phase out“serologic weak D phenotype”and resolve D types with RHD genotyping including weak D type 4[J].Transfusion,2020,60(4):855-859. [11] TAN J C,ARMSTRONG N J,YUAN F F,et al.Identificat ion of genetic polymorphisms that predict responder/non-responder profiles to the RhD antigen[J].Mol Immunol,2015,68(2 pt c):628-633. [12] VILLALBA A,SANTIAGO M,FREIRIA C,et al.Anti-D alloimmunization after RhD-positive platelet transfusion in RhD-negative women under 55 years diagnosed with acute leukemia: results of a retrospective study[J].Transfus Med Hemother,2018,45(3):162-166. [13] ARTHUR C M,PATEL S R,SMITH N H,et al.Antigen density dictates immune responsiveness following red blood cell transfusion[J].J Immunol,2017,198(7): 2671-2680. [14] KWON D H,SANDLER S G,FLEGEL W A.DEL phenotype[J].Immunohematology,2019,33(3):125-132. [15] SCHONEWILLE H,DOXIADIS I I,LEVERING W H,et al.HLA-DRB1 associations in individuals with single and multiple clinically relevant red blood cell antibodies[J].Transfusion,2014,54(8):1971-1980. [16] VERDUIN E P,BRAND A,VAN DE WATERING L M G,et al.The HLA-DRB1*15 phenotype is associated with multiple red blood cell and HLA antibody responsiveness[J].Transfusion,2016,56(7):1849-1856. [17] BAO W,ZHONG H,LI X,et al.Immune regulation in chronically transfused allo-antibody responder and nonresponder patients with sickle cell disease and β-thalassemia major[J].Am J Hematol,2011,86(12): 1001-1006. [18] PAL M,BAO W,WANG R,et al.Hemolysis inhibits humoral B-cell responses and modulates alloimmunization risk in patients with sickle cell disease[J].Blood,2021,137(2):269-280. [19] KING C,TANGYE S G,MACKAY C R.T follicular helper (TFH) cells in normal and dysregulated immune responses[J].Annu Rev Immunol,2008,26(1): 741-766. [20] MCGUIRE H M,VOGELZANG A,WARREN J,et al.IL-21 and IL-4 collaborate to shape T-dependent antibody responses[J].J Immunol,2015,195(11): 5123-5135. [21] BÉLANGER S,CROTTY S.Dances with cytokines,featur ing T_FH cells,IL-21,IL-4 and B cells[J].Nat Immunol,2016,17(10):1135-1136. [22] GODEFROY E,ZHONG H,PHAM P,et al.TIGIT-positive circulating follicular helper T cells display robust B-cell help functions: potential role in sickle cell alloimmunization[J].Haematologica,2015,100(11):1415-1425. [23] NATARAJAN P,LIU D,PATEL S R,et al.CD4 depletion or CD40L blockade results in antigen-specific tolerance in a red blood cell alloimmunization model[J].Front Immunol,2017,8:907. [24] GIBB D R,LIU J C,NATARAJAN P,et al.Type I IFN is necessary and sufficient for inflammation-induced red blood cell alloimmunization in mice[J].J Immunol,2017,199(3):1041-1050. [25] MENER A,PATEL S R,ARTHUR C M,et al.Complement serves as a switch between CD4+ T cell-independent and -dependent RBC antibody responses[J].JCI Insight,2018,3(22):e121631. [26] CALABRO S,GALLMAN A,GOWTHAMAN U,et al.Bridging channel dendritic cells induce immunity to transfused red blood cells[J].J Exp Med,2016,213(6): 887-896. [27] ARNEJA A,SALAZAR J E,JIANG W,et al.Interleukin-6 receptor-alpha signaling drives anti-RBC alloantibody production and T-follicular helper cell differentiation in a murine model of red blood cell alloimmunization[J].Haematologica,2016,101(11): e440-e444. [28] FASANO R M,BOOTH G S,MILES M,et al.Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease[J].Br J Haematol,2015,168(2): 291-300. [29] PAPAY P,HACKNER K,VOGELSANG H,et al.High risk of transfusion-induced alloimmunization of patients with inflammatory bowel disease[J].Am J Med,2012,125(7):717.e1-717.e8. [30] HANCHARD N A,MOULDS J M,BELMONT J W,et al.A genome-wide screen for large-effect alloimmunization susceptibility loci among red blood cell transfusion recipients with sickle cell disease[J].Transfus Med Hemother,2014,41(6):453-461. [31] SIMMONS D P,SAVAGE W J.Hemolysis from ABO incompatibility[J].Hematol Oncol Clin North Am,2015,29(3):429-443. [32] BERENTSEN S,SUNDIC T.Red blood cell destruction in autoimmune hemolytic Anemia: role of complement and potential new targets for therapy[J].Biomed Res Int,2015,2015:1-11. [33] EINARSDOTTIR H K,STAPLETON N M,SCHERJON S,et al.On the perplexingly low rate of transport of IgG2 across the human placenta[J].PLoS One,2014,9(9):e108319. [34] VIDARSSON G,DEKKERS G,RISPENS T.IgG subclasses and allotypes: from structure to effector functions[J].Front Immunol,2014,5:520. [35] 马印图,王更银,李烛,等.母婴血型不合新生儿溶血病IgG抗体亚型分析[J].临床输血与检验,2020,22(3): 269-272. [36] KUMPEL B M,SALDOVA R,KOELEMAN C A M,et al.Anti-D monoclonal antibodies from 23 human and rodent cell lines display diverse IgG Fc-glycosylation profiles that determine their clinical efficacy[J].Sci Rep,2020,10(1):1464. [37] KAPUR R,DELLA VALLE L,SONNEVELD M,et al.Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn[J].Br J Haematol,2014,166(6):936-945. [38] SONNEVELD M E,KOELEWIJN J,DE HAAS M,et al.Antigen specificity determines anti-red blood cell IgG-Fc alloantibody glycosylation and thereby severity of haemolytic disease of the fetus and newborn[J].Br J Haematol,2017,176(4):651-660. [39] JENNEWEIN M F,ABU-RAYA B,JIANG Y,et al.Transfer of maternal immunity and programming of the newborn immune system[J].Semin Immunopathol,2017,39(6):605-613. [40] MARTINEZ D R,FONG Y,LI S H,et al.Fc characteristics mediate selective placental transfer of IgG in HIV-infected women[J].Cell,2019,178(1): 190-201.e11. [41] JENNEWEIN M F,GOLDFARB I,DOLATSHAHI S,et al.Fc glycan-mediated regulation of placental antibody transfer[J].Cell,2019,178(1):202-215.e14. [42] YASUDA H,OHTO H,NOLLET K E,et al.Hemolytic disease of the fetus and newborn with late-onset Anemia due to anti-M: a case report and review of the Japanese literature[J].Transfus Med Rev,2014,28(1): 1-6. [43] KAUR G,BASU S,KAUR P,et al.Clinically significant anti M antibodies——a report of two cases[J].Transfus Apher Sci,2012,47(3):259-261. [44] ZWIERS C,KOELEWIJN J M,VERMIJ L,et al.ABO incompatibility and RhIG immunoprophylaxis protect against non-D alloimmunization by pregnancy[J].Transfusion,2018,58(7):1611-1617. [45] Society for Maternal-Fetal Medicine (SMFM),BERRY S M,STONE J,et al.Fetal blood sampling[J].Am J Obstet Gynecol,2013,209(3):170-180. [46] SALOMON L J,SOTIRIADIS A,WULFF C B,et al.Risk of miscarriage following amniocentesis or chorionic villus sampling: systematic review of literature and updated meta-analysis[J].Ultrasound Obstet Gynecol,2019,54(4):442-451. [47] LO Y M,CORBETTA N,CHAMBERLAIN P F,et al.Presence of fetal DNA in maternal plasma and serum[J].Lancet,1997,350(9076):485-487. [48] LO Y M,TEIN M S,LAU T K,et al.Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis[J].Am J Hum Genet,1998,62(4):768-775. [49] SMID M,GALBIATI S,VASSALLO A,et al.No evidence of fetal DNA persistence in maternal plasma after pregnancy[J].Hum Genet,2003,112(5/6):617-618. [50] YU S C,LEE S W,JIANG P,et al.High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing[J].Clin Chem,2013,59(8):1228-1237. [51] FINNING K,MARTIN P,SUMMERS J,et al.Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study[J].BMJ,2008,336(7648):816-818. [52] QURESHI H,MASSEY E,KIRWAN D,et al.BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn[J].Transfus Med,2014,24(1):8-20. [53] CHITTY L S,FINNING K,WADE A,et al.Diagnostic accuracy of routine antenatal determination of fetal RHD status across gestation: population based cohort study[J].BMJ,2014,349:g5243. [54] DE HAAS M,THURIK F F,VAN DER PLOEG C P,et al.Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands[J].BMJ,2016,355: i5789. [55] CLAUSEN F B,STEFFENSEN R,CHRISTIANSEN M,et al.Routine noninvasive prenatal screening for fetal RHD in plasma of RhD-negative pregnant women-2 years of screening experience from Denmark[J].Prenat Diagn,2014,34(10):1000-1005. [56] CLAUSEN F B,RIENECK K,KROG G R,et al.Noninvasive antenatal screening for fetal RHD in RhD negative women to guide targeted anti-D prophylaxis[J].Methods Mol Biol,2019,1885:347-359. [57] WIKMAN A T,TIBLAD E,KARLSSON A,et al.Noninvasive single-exon fetal RHD determination in a routine screening program in early pregnancy[J].Obstet Gynecol,2012,120(2 Pt 1):227-234. [58] BENACHI A,DELAHAYE S,LETICEE N,et al.Impact of non-invasive fetal RhD genotyping on management costs of rhesus-D negative patients: results of a French pilot study[J].Eur J Obstet Gynecol Reprod Biol,2012,162(1):28-32. [59] TEITELBAUM L,METCALFE A,CLARKE G,et al.Costs and benefits of non-invasive fetal RhD determination[J].Ultrasound Obstet Gynecol,2015,45(1):84-88. [60] SIN S T K,JIANG P Y,DENG J E,et al.Identification and characterization of extrachromosomal circular DNA in maternal plasma[J].PNAS,2020,117(3):1658-1665. [61] ACOG Practice Bulletin No. 192: Management of Alloimmunization During Pregnancy[J]. Obstet Gynecol, 2018. 131(3):e82-e90. [62] 贺坤华,林裕翔,徐银霞,等.罕见IgG抗PP1PK致新生儿溶血病1例[J].南京医科大学学报(自然科学版),2021,41(2):310-312. [63] SARIHI R,AHMADNEJAD M,MOHAMMADI S,et al.Hemolytic disease of the fetus and newborn caused by anti-Hr0 in a 27-year-old female with Dc- phenotype: a case report[J].Transfus Apher Sci,2021,60(1):102913. [64] 李志强. RhD抗原阴性孕产妇血液安全管理专家共识[J].中国输血杂志,2017,30(10): 1085-1091. [65] 肖军,郑飞天,陈柄澔,等.O型孕产妇IgG抗体效价与胎儿新生儿溶血病关系的meta分析[J].中国输血杂志,2020,33(9):925-928. [66] Green-top guideline no.65: the management of women with red cell antibodies during pregnancy[J].Obstet Gynecol,2014,16(3):224. [67] WHITE J,QURESHI H,MASSEY E,et al.Guideline for blood grouping and red cell antibody testing in pregnancy[J].Transfus Med,2016,26(4):246-263. [68] SLOOTWEG Y M,LINDENBURG I T,KOELEWIJN J M,et al.Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management[J].Am J Obstet Gynecol,2018,219(4):393.e1-393.e8. [69] VAN WAMELEN D J,KLUMPER F J,DE HAAS M,et al.Obstetric history and antibody titer in estimating severity of kell alloimmunization in pregnancy[J].Obstet Gynecol,2007,109(5):1093-1098. [70] SLOOTWEG Y M,LINDENBURG I T,KOELEWIJN J M,et al.Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management[J].Am J Obstet Gynecol,2018,219(4):393.e1-393.e8. [71] 马印图,王更银,李烛,等.微柱凝胶技术检测血型抗体IgG亚型的应用评价[J].临床血液学杂志(输血与检验),2019,32(2):106-108. [72] 马印图,王更银,李玉秋,等.微柱凝胶技术检测血型抗体IgG亚型试验方法的建立[J].临床血液学杂志(输血与检验),2018,31(4):253-256. [73] TONG T N,BURKE-MURPHY E,SAKAC D,et al.Optimal conditions for the performance of a monocyte monolayer assay[J].Transfusion,2016,56(11):2680-2690. [74] TONG T N,CEN S,BRANCH D R.The monocyte monolayer assay: past,present and future[J].Transfus Med Rev,2019,33(1):24-28. [75] OEPKES D,VAN KAMP I L,SIMON M J,et al.Clinical value of an antibody-dependent cell-mediated cytotoxicity assay in the management of Rh D alloimmunization[J].Am J Obstet Gynecol,2001,184(5):1015-1020. [76] LUCAS G F,HADLEY A G,NANCE S J,et al.Predicting hemolytic disease of the newborn: a comparison of the monocyte monolayer assay and the chemiluminescence test[J].Transfusion,1993,33(6):484-487. [77] Society for Maternal-Fetal Medicine (SMFM),ORG P,MARI G,et al.Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #8: the fetus at risk for Anemia—diagnosis and management[J].Am J Obstet Gynecol,2015,212(6):697-710. [78] MARI G.Noninvasive diagnosis by Doppler ultrasonography of fetal Anemia due to maternal red-cell alloimmunization[J].Obstet Gynecol Surv,2000,55(6):341-342. |
| [1] | 马铭梓, 王秋实, 于洋. 中国人群新生儿同种免疫性血小板减少症36例文献回顾性分析*[J]. 临床输血与检验, 2021, 23(5): 585-592. |
| [2] | 马婷, 孙杨, 邢莉莉, 牛佳萌, 王秋实, 杨江存. 全国住院输血新生儿疾病谱前五名疾病的血液检测指标分析*[J]. 临床输血与检验, 2021, 23(5): 593-599. |
| [3] | 蔡晟阳, 徐军, 陈学军, 尹明伟, 周超, 马继华, 李灵. 浙江地区12月龄内婴儿的ABO血型抗体检出变化初探[J]. 临床输血与检验, 2021, 23(5): 600-603. |
| [4] | 阳智芬, 邹彬彬, 曹丽群, 谢毓滨. 一例抗HLA抗体引起的新生儿同种免疫性血小板减少性紫癜*[J]. 临床输血与检验, 2021, 23(5): 668-670. |
| [5] | 徐文莹, 任新雯, 井忠翠, 刘爱萍, 刘耿君, 王海燕. ABO新生儿溶血病患儿溶血三项试验和就诊日龄与血清总胆红素水平的关系研究*[J]. 临床输血与检验, 2021, 23(3): 306-309. |
| [6] | 陈凤, 郑洋洋. 药物包被红细胞法和药物添加法检测358例贫血患者抗生素类药物性抗体结果分析*[J]. 临床输血与检验, 2021, 23(3): 327-332. |
| [7] | 王晓宁, 孙长杰, 王宇飞, 卢伟伟, 刘冰. O型患者非同型肝移植引发免疫性过客淋巴细胞综合征1例[J]. 临床输血与检验, 2021, 23(3): 391-394. |
| [8] | 刘倩, 王笑欢, 郭凯, 牛子健, 宋珊珊, 郭婧, 马曙轩. 新生儿换血前后实验室指标的变化趋势*[J]. 临床输血与检验, 2021, 23(2): 177-180. |
| [9] | 甘珊, 段灵, 胡红兵. 新生儿高胆红素血症换血治疗用血情况分析*[J]. 临床输血与检验, 2021, 23(2): 185-188. |
| [10] | 中国输血协会免疫血液学专业委员会. 胎儿新生儿溶血病实验室检测专家共识*[J]. 临床输血与检验, 2021, 23(1): 20-24. |
| [11] | 李翠莹. 胎儿新生儿溶血病的诊疗策略探讨*[J]. 临床输血与检验, 2021, 23(1): 24-28. |
| [12] | 范秀, 肖军, 李翠莹. 抗-D免疫球蛋白预防RhD血型不合胎儿新生儿溶血病的研究进展*[J]. 临床输血与检验, 2021, 23(1): 29-32. |
| [13] | 雷慧芬, 樊凤艳, 肖军, 李小薇, 李翠莹. 国内医疗机构胎儿新生儿溶血病免疫血液学检测情况分析*[J]. 临床输血与检验, 2021, 23(1): 33-38. |
| [14] | 王文婷, 党盼玉, 张保萍, 胡兴斌, 安群星, 尹文. 抗-D抗体致新生儿溶血病的输血策略及其预后疗效评估分析[J]. 临床输血与检验, 2021, 23(1): 38-40. |
| [15] | 范亮峰, 陆琼, 姜跃琴, 王中英, 向东. 人血液经56℃孵育处理后溶血率及血型抗原抗体变化*[J]. 临床输血与检验, 2021, 23(1): 54-60. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
